MDxHealth SA (MDXH.BR)
BE0974461940 - Common Stock
We assign a fundamental rating of 2 out of 10 to MDXH. MDXH was compared to 76 industry peers in the Biotechnology industry. Both the profitability and financial health of MDXH have multiple concerns. MDXH is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
MDXH had negative earnings in the past year.
In the past 5 years MDXH always reported negative net income.
In the past 5 years MDXH always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of MDXH (-51.61%) is worse than 63.64% of its industry peers.
MDXH's Return On Equity of -393.48% is on the low side compared to the rest of the industry. MDXH is outperformed by 75.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.61% | ||
| ROE | -393.48% | ||
| ROIC | N/A |
ROA(3y)-55.15%
ROA(5y)-64.23%
ROE(3y)-343.17%
ROE(5y)-262.12%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDXH's Gross Margin of 59.66% is fine compared to the rest of the industry. MDXH outperforms 64.94% of its industry peers.
In the last couple of years the Gross Margin of MDXH has declined.
The Profit Margin and Operating Margin are not available for MDXH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 59.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-6.79%
2. Health
2.1 Basic Checks
MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MDXH has more shares outstanding
The number of shares outstanding for MDXH has been increased compared to 5 years ago.
MDXH has a worse debt/assets ratio than last year.
2.2 Solvency
MDXH has an Altman-Z score of -3.05. This is a bad value and indicates that MDXH is not financially healthy and even has some risk of bankruptcy.
MDXH's Altman-Z score of -3.05 is on the low side compared to the rest of the industry. MDXH is outperformed by 71.43% of its industry peers.
A Debt/Equity ratio of 2.17 is on the high side and indicates that MDXH has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 2.17, MDXH is doing worse than 75.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.17 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.05 |
ROIC/WACCN/A
WACC6.93%
2.3 Liquidity
MDXH has a Current Ratio of 2.43. This indicates that MDXH is financially healthy and has no problem in meeting its short term obligations.
MDXH has a Current ratio of 2.43. This is comparable to the rest of the industry: MDXH outperforms 44.16% of its industry peers.
MDXH has a Quick Ratio of 2.27. This indicates that MDXH is financially healthy and has no problem in meeting its short term obligations.
MDXH has a Quick ratio (2.27) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.43 | ||
| Quick Ratio | 2.27 |
3. Growth
3.1 Past
MDXH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.81%.
The Revenue has grown by 66.59% in the past year. This is a very strong growth!
Measured over the past years, MDXH shows a decrease in Revenue. The Revenue has been decreasing by -1.77% on average per year.
EPS 1Y (TTM)-16.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)66.59%
Revenue growth 3Y46.47%
Revenue growth 5Y-1.77%
Sales Q2Q%73.48%
3.2 Future
Based on estimates for the next years, MDXH will show a very strong growth in Earnings Per Share. The EPS will grow by 51.91% on average per year.
MDXH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.69% yearly.
EPS Next Y-6519.8%
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%
EPS Next 5Y51.91%
Revenue Next Year84.81%
Revenue Next 2Y47.5%
Revenue Next 3Y43.11%
Revenue Next 5Y27.69%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MDXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDXH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as MDXH's earnings are expected to decrease with -49.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%
5. Dividend
5.1 Amount
MDXH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MDxHealth SA
EBR:MDXH (12/15/2023, 7:00:00 PM)
3.02
-0.12 (-3.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap82.41M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.61% | ||
| ROE | -393.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 59.66% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.17 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.43 | ||
| Quick Ratio | 2.27 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-16.81%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-6519.8%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)66.59%
Revenue growth 3Y46.47%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y